Back to top

Analyst Blog

Zacks Equity Research

Earnings Miss at Hi-Tech Pharmacal

JAZZ LCI

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Hi-Tech Pharmacal Co., Inc. reported fourth quarter fiscal 2013 (ended Apr 30, 2013) earnings of 50 cents per share, well below the Zacks Consensus Estimate of 68 cents and down 38.3% from the year-ago period. Lower-than-expected revenues contributed to the earnings miss in the final quarter of fiscal 2013.

Fourth quarter revenues were $58.5 million, down 4.6% year over year. Revenues missed the Zacks Consensus Estimate of $66 million.

Revenues at Hi-Tech Pharmacal  were hurt by lower sales of Fluticasone nasal spray. Lower pricing hurt the sales of the drug. A slower-than-normal start to the allergy season also led to the weak revenues recorded in the quarter..

Fiscal year 2013 earnings were $2.28 per share, down 40.8% year over year. The Zacks Consensus Estimate for fiscal 2013 stood at $2.40 per share.  Revenues in 2013 rose 10.4% year over year to $232.4 million. Revenues for 2013 were below the Zacks Consensus Estimate of $239 million.

Research and development expenses for fiscal 2013, increased 41.4% year over year to $17.3 million due to increased spending on internal projects for the generic pharmaceuticals division. Selling, general and administrative expenses rose 19.9% to $53.6 million in fiscal 2013 due to costs incurred towards restructuring of sales organization.

Segmental Details

Hi-Tech Pharmacal reports revenues under three segments – generic pharmaceuticals (Hi-tech generic), OTC branded pharmaceuticals (Health Care Products) and prescription brands (ECR).

Revenues at the generic pharmaceuticals segment in the reported quarter were down 7.2% year over year to $48.9 million. Lower revenues of Fluticasone Propionate nasal spray (down 31% year over year to $19.6 million) were primarily responsible for the decline.

Revenues at the Health Care Products division were down 7% from the prior-year quarter to $4.9 million. Sales continued to be affected by lower sales of diabetes drug Tussin.

Sales from the ECR division increased 40% to $4.7 million mainly driven by TussiCaps and Bupap sales.

Outlook

Hi-Tech Pharmacal expects a top line growth this year across all its businesses. The new generic launches will drive the generic increase. However, Hi-Tech Pharmacal expects declining sales of Fluticasone. Hi-Tech Pharmacal expects double-digit growth in its Health Care Products and ECR divisions.

Hi-Tech Pharmacal carries a Zacks Rank #3 (Hold). Right now, companies like Santarus, Inc. , Lannett Company, Inc. (LCI - Snapshot Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BOFL HOLDING BOFI 85.58 +5.32%
DIXIE GROUP DXYN 15.41 +4.98%
CELL THERAPE CTIC 3.13 +4.68%
RAMBUS INC RMBS 12.23 +3.73%
DAIMLER AG DDAIF 93.03 +2.95%